Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ARCA biopharma, Inc. (ABIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0700-0.0600 (-2.82%)
At close: 04:00PM EDT
1.9900 -0.08 (-3.86%)
After hours: 06:13PM EDT
Advertisement

ARCA biopharma, Inc.

10170 Church Ranch Way
Suite 100
Westminster, CO 80021
United States
720 940 2200
https://www.arcabio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees17

Key Executives

NameTitlePayExercisedYear Born
Dr. Michael R. Bristow M.D., Ph.D.Co-Founder, Pres, CEO & Director363.56kN/A1945
Mr. Thomas A. KeuerChief Operating Officer360.58kN/A1959
Mr. Christopher D. OzeroffSr. VP, Gen. Counsel & Sec.318.86kN/A1959
Mr. C. Jeffrey Dekker CPAChief Financial OfficerN/AN/A1965
Dr. Debra Marshall FACC, M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

Corporate Governance

ARCA biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement